Cell Source, Inc. is a biotechnology company, which focuses on developing cell therapy treatments based on the management of immune tolerance. The company is headquartered in New York City, New York. The company went IPO on 2014-01-14. The firm is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The firm's wholly owned subsidiary is Cell Source Limited (CSL).
Follow-Up Questions
Cell Source Inc의 CEO는 누구입니까?
Mr. Itamar Shimrat은 2014부터 회사에 합류한 Cell Source Inc의 Chief Executive Officer입니다.
CLCS 주식의 가격 성능은 어떻습니까?
CLCS의 현재 가격은 $0.4이며, 전 거래일에 decreased 0% 하였습니다.
Cell Source Inc의 주요 사업 주제나 업종은 무엇입니까?
Cell Source Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다